Epithelial Ovarian Cancer

P3, N=384, Recruiting, Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting

Importantly, the in vivo results confirmed that RA induced ferroptosis and dramatically suppressed the growth of A2780/DDP transplanted tumours. Taken together, we revealed for the first time that VEPH1 is the direct target for RA, and ferroptosis contributes to RA-triggered anti-tumour effect on cisplatin-resistant EOC, which provides new insights into the therapeutic application of RA against EOC chemoresistance.

Prognosis appears to be driven primarily by tumor biology, stage, and surgical outcome rather than the presence of endometriosis itself. The online version contains supplementary material available at 10.1186/s12885-026-15980-w.

Together, these findings define RHOV as a unique detachment-sensitive Rho GTPase and establish RHOV as a critical and necessary mediator of early adaptations that prime ovarian cancer cells for peritoneal metastatic progression. This work provides key insights into the molecular vulnerabilities of disseminating tumor cells, establishes the targeting of early molecular adaptations following matrix detachment as a potential therapeutic strategy for metastatic disease, and uncovers functions of an understudied member of the Rho GTPase family.

P1, N=1, Terminated, Instil Bio | N=51 --> 1 | Trial completion date: Nov 2039 --> Mar 2026 | Active, not recruiting --> Terminated; The study was terminated early due to discontinuation of development of the investigational program

In this real-world retrospective cohort, BRCA mutation status was associated with increased risk of clinically significant olaparib-related toxicity. These findings suggest that BRCA mutation status may help identify patients at higher risk of adverse events and support closer toxicity monitoring and individualized dose management during maintenance therapy.

P1, N=27, Recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Mar 2026 --> Apr 2036 | Trial primary completion date: Mar 2026 --> Apr 2036

Pembrolizumab plus weekly paclitaxel, with or without bevacizumab, significantly improved progression-free survival and overall survival in participants with platinum-resistant recurrent ovarian cancer who had received one to two previous systemic regimens, supporting this regimen as a new treatment option for this population.

We discuss the challenges associated with their validation and clinical translation, as well as their relevance for the development of vaccines and adoptive T cell-based therapies. Finally, we illustrate these concepts using epithelial ovarian cancer as a representative model of low-mutational-burden tumors, where lncRNA-derived neoantigens may help overcome current limitations of immunotherapy and enable patient stratification for personalized treatment approaches.

SLC2A1-AS1 may drive the progression and recurrence of EOC through the miR-508-5p/FOXO1 axis.

We studied MRI immune cell tracking in a murine model of ovarian cancer using a clinically relevant treatment combination of DPX-Survivac, anti-PD-1, and an intermittent low dose of Cyclophosphamide (CPA). The density of SPIO-labeled myeloid and CD8+ T cells in tumors was higher in the treatment group than in the control group. This study provides insights into how MRI can be used in concert with biological assays to study how immunotherapy and chemotherapy combinations exert their antitumor effects.

P3, N=538, Active, not recruiting, The Netherlands Cancer Institute | Recruiting --> Active, not recruiting | Trial completion date: Apr 2026 --> Dec 2028 | Trial primary completion date: Apr 2025 --> Apr 2028